Literature DB >> 28102514

Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality.

M Papadimitriou-Olivgeris1, F Fligou2, C Bartzavali3, A Zotou2, A Spyropoulou3, K Koutsileou2, S Vamvakopoulou3, N Sioulas2, V Karamouzos2, E D Anastassiou3, I Spiliopoulou3, M Christofidou3, M Marangos4.   

Abstract

A significant increase in carbapenemase-producing Klebsiella pneumoniae (CP-Kp) bacteraemias has been observed worldwide. The objective of the present work was to study the risk factors and predictors of mortality of CP-Kp bacteraemias among critically ill patients. During a 4-year period (2012-3015), a matched 1:2 case-control study was conducted. Klebsiella pneumoniae was identified by Vitek 2 technology. Antibiotic susceptibility was performed by the agar disc diffusion method and Etest. The presence of the bla KPC, bla VIM and bla NDM genes was confirmed by polymerase chain reaction (PCR). Epidemiologic data were collected from the intensive care unit (ICU) computerised database. One hundred and thirty-nine patients who developed a CP-Kp bacteraemia were matched with 278 patients. The majority of isolates (128; 92.1%) carried the bla KPC gene, seven carried both bla KPC and bla VIM, three bla VIM and one carried bla NDM. Risk factors for the development of CP-Kp bacteraemia were administration of tigecycline and number of antibiotics administered prior to CP-Kp bacteraemia. Overall, the 30-day mortality was 36.0%. Multivariate analysis revealed septic shock, Simplified Acute Physiology Score II (SAPS II) upon infection onset, adjunctive corticosteroid administration and parenteral nutrition as independent predictors of mortality, while treatment with a combination of appropriate antibiotics was identified as a predictor of good prognosis. Among septic shock patients (n = 74), Sequential Organ Failure Assessment (SOFA) score upon infection onset, adjunctive corticosteroid administration and strain carrying the bla KPC gene were independently associated with mortality, while the administration of combination treatment was identified as a predictor of a good prognosis. The administration of tigecycline predisposes to the induction of bacteraemia. Appropriate antibiotic treatment is associated with better survival, while concomitant corticosteroid treatment is associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28102514     DOI: 10.1007/s10096-017-2899-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

2.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

3.  A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates.

Authors:  Aikaterini Spyropoulou; Matthaios Papadimitriou-Olivgeris; Christina Bartzavali; Sophia Vamvakopoulou; Markos Marangos; Iris Spiliopoulou; Evangelos D Anastassiou; Myrto Christofidou
Journal:  J Med Microbiol       Date:  2015-12-23       Impact factor: 2.472

4.  Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  M Falcone; A Russo; A Iacovelli; G Restuccia; G Ceccarelli; A Giordano; A Farcomeni; A Morelli; M Venditti
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

Review 5.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.

Authors:  George L Daikos; Sophia Tsaousi; Leonidas S Tzouvelekis; Ioannis Anyfantis; Mina Psichogiou; Athina Argyropoulou; Ioanna Stefanou; Vana Sypsa; Vivi Miriagou; Martha Nepka; Sarah Georgiadou; Antonis Markogiannakis; Dimitris Goukos; Athanasios Skoutelis
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

7.  Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.

Authors:  Matthaios Papadimitriou-Olivgeris; Markos Marangos; Myrto Christofidou; Fotini Fligou; Christina Bartzavali; Eleftheria S Panteli; Sophia Vamvakopoulou; Kriton S Filos; Evangelos D Anastassiou
Journal:  Scand J Infect Dis       Date:  2014-07-14

8.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

9.  Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.

Authors:  George L Daikos; Evangelos Vryonis; Mina Psichogiou; Leonidas S Tzouvelekis; Stavros Liatis; Panayiotis Petrikkos; Chris Kosmidis; Panayotis T Tassios; Giorgos Bamias; Athanasios Skoutelis
Journal:  J Antimicrob Chemother       Date:  2010-01-27       Impact factor: 5.790

10.  High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.

Authors:  Gennaro De Pascale; Luca Montini; Mariano Pennisi; Valentina Bernini; Riccardo Maviglia; Giuseppe Bello; Teresa Spanu; Mario Tumbarello; Massimo Antonelli
Journal:  Crit Care       Date:  2014-05-05       Impact factor: 9.097

View more
  11 in total

1.  Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies.

Authors:  D R Giacobbe; A E Maraolo; C Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-21       Impact factor: 3.267

2.  Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.

Authors:  G L Drusano; Ryan K Shields; Nino Mtchedlidze; M Hong Nguyen; Cornelius J Clancy; Michael Vicciarelli; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 3.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 4.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

5.  Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital.

Authors:  Qinjie Liu; Jianan Ren; Xiuwen Wu; Gefei Wang; Zhiwei Wang; Jie Wu; Jinjian Huang; Tianyu Lu; Jieshou Li
Journal:  BMC Infect Dis       Date:  2017-09-21       Impact factor: 3.090

6.  Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL-Enterobacterales ventilator-associated pneumonia in mechanically ventilated ESBL carriers.

Authors:  Olivier Andremont; Laurence Armand-Lefevre; Claire Dupuis; Etienne de Montmollin; Stéphane Ruckly; Jean-Christophe Lucet; Roland Smonig; Eric Magalhaes; Etienne Ruppé; Bruno Mourvillier; Jordane Lebut; Mathilde Lermuzeaux; Romain Sonneville; Lila Bouadma; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2020-04-20       Impact factor: 17.440

7.  Mortality of Pandrug-Resistant Klebsiella pneumoniae Bloodstream Infections in Critically Ill Patients: A Retrospective Cohort of 115 Episodes.

Authors:  Matthaios Papadimitriou-Olivgeris; Christina Bartzavali; Alexandra Georgakopoulou; Fevronia Kolonitsiou; Chrisavgi Papamichail; Iris Spiliopoulou; Myrto Christofidou; Fotini Fligou; Markos Marangos
Journal:  Antibiotics (Basel)       Date:  2021-01-15

8.  Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016).

Authors:  Matthaios Papadimitriou-Olivgeris; Fevronia Kolonitsiou; Vasileios Karamouzos; Katerina Tsilipounidaki; Alexandra Nikolopoulou; Fotini Fligou; Markos Marangos; Efthimia Petinaki; Iris Spiliopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-02       Impact factor: 3.267

9.  The role of the bla KPC gene in antimicrobial resistance of Klebsiella pneumoniae.

Authors:  Atossa Ghasemnejad; Monir Doudi; Nour Amirmozafari
Journal:  Iran J Microbiol       Date:  2019-08

10.  Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset).

Authors:  Akosua A Agyeman; Phillip J Bergen; Gauri G Rao; Roger L Nation; Cornelia B Landersdorfer
Journal:  Data Brief       Date:  2019-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.